NuCana

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

EDINBURGH, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022, the Regional Court of Dusseldorf (the “Court”) issued a judgement on July 7, 2022 that Gilead Sciences Ireland UC and Gilead Sciences GmbH (together, “Gilead”) infringe NuCana's composition of matter claims in European Patent 2955190 (the “'190 patent”) through their sales of Sovaldi®, Harvoni®, Vosevi® and Epclusa® in Germany.

German Court Rules that Gilead's Sofosbuvir Infringes NuCana's ‘190 Patent

NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia

NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer

NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

EDINBURGH, United Kingdom, June 01, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Jefferies Healthcare Conference.

NuCana to Participate in the 2022 Jefferies Healthcare Conference

Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022

NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update

Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro

NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022

NuCana PLC Sponsored ADR (NCNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 57.3% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)

Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis

NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022

NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study

Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.

Is NuCana PLC Sponsored ADR (NCNA) Outperforming Other Medical Stocks This Year?

NuCana recently enrolled the required number of patients to conduct a first interim analysis in Acelarin‘s Phase III study in biliary tract cancer in the 1H of 2022. Acelarin has both the FDA's Fast Track Designation and Orphan Drug Designation.

NuCana: Preparing For A Critical 2022

Enrolled Required Number of Patients to Conduct First Interim Analysis in Phase 3 Biliary Tract Cancer Study in the First Half of 2022

NuCana Reports Third Quarter 2021 Financial Results and Provides Business Update

Former Amgen SVP of Global Development and R&D Strategy and Operations Brings Substantial Drug Development Experience to NuCana Former Amgen SVP of Global Development and R&D Strategy and Operations Brings Substantial Drug Development Experience to NuCana

NuCana Appoints Elliott M. Levy, M.D.

NuCana (NCNA) stock is surging higher on Wednesday after the company revealed fast track designation from the FDA for Acelarin. The post NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing appeared first on InvestorPlace.

NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing

The stock price of NuCana PLC (NASDAQ: NCNA) increased by over 20% during intraday trading today. This is why it happened.

NCNA Stock: Why It Substantially Increased Today

The FDA has granted Fast Track designation to NuCana plc's (NASDAQ: NCNA) Acelarin (NUC-1031) for the first-line treatment of patients with advanced biliary tract cancer. The Company recently announced the enrollment of 418 evaluable patients in the Phase 3 study, which is expected to enable the first interim analysis in 1H of 2022.

Why Are NuCana Shares Moving Higher On Wednesday?

EDINBURGH, United Kingdom, Sept. 29, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin (NUC-1031), currently being evaluated in a Phase III study (NuTide:121) for the first-line treatment of patients with advanced biliary tract cancer. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address an unmet medical need.

NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer

NUC-3373 Continues to Demonstrate Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer

NuCana Announces Four Poster Presentations at the ESMO Congress 2021

Enrollment of 418 Evaluable Patients Expected to Enable First Interim Analysis in the First Half of 2022

NuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary Tract Cancer Study

NuCana: The Market Continues To Overlook Its ProTide Platform Technology

GameStop

Cassava Sciences Inc

Electrameccanica

trivago

Verb Technology Company Inc

Alkaline Water Company Inc (The)

The risk in these inexpensive bargain stocks is offset by their upside for investors looking for a little more spice in their portfolio. The post 7 Bargain Stocks to Buy Under $5 With the Right Catalysts appeared first on InvestorPlace.

7 Bargain Stocks to Buy Under $5 With the Right Catalysts

EDINBURGH, United Kingdom, Aug. 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

NuCana Reports Second Quarter 2021 Financial Results and Provides Business Update

China Online Education Group

Ceragon Networks

Rockwell Medical

Here's a list of interesting penny stocks to buy that have lucrative prospects if you're willing to risk it for tremendous upside. The post 7 Penny Stocks to Buy if You Want Potential Multibaggers appeared first on InvestorPlace.

7 Penny Stocks to Buy if You Want Potential Multibaggers

NuCana has been on my watch list over the past year due to its intriguing ProTide platform technology, which could generate multiple oncology drugs that can outperform the current standard of care. The share price has been under pressure since January and has been ground into an attractive valuation. I believe there is an astonishing risk-reward at these prices.

NuCana: Starting A Speculative Position At An Astonishing Risk-Reward

Presented Encouraging Clinical Data at ASCO-GI and AACR

News for NuCana Stock (NCNA)